.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,916,911

« Back to Dashboard

Details for Patent: 5,916,911

Title: Amino ceramide--like compounds and therapeutic methods of use
Abstract:Novel amino compounds are provided which inhibit glucosyl ceramide (GlcCer) formation by inhibiting the enzyme GlcCer synthase, thereby lowering the level of glycosphingolipids. The compounds of the present invention have improved GlcCer synthase inhibition activity and are therefore highly useful in therapeutic methods for treating various conditions and diseases associated with altered glycosphingolipid levels.
Inventor(s): Shayman; James A. (Ann Arbor, MI), Radin; Norman S. (Ann Arbor, MI)
Assignee: The Regents Of The University Of Michigan (Ann Arbor, MI)
Filing Date:Sep 05, 1996
Application Number:08/708,574
Claims:1. A method for inhibiting the growth of cancer cells in a mammal, wherein said cancer cells are sensitive to the compounds below, comprising the step of administering to the mammal a therapeutically effective amount of a compound selected from the group consisting of compounds of the formula: ##STR5## where R.sub.1 is an aromatic structure, an alicyclic structure, a branched aliphatic structure or a linear aliphatic group having 5 to 15 carbons;

R.sup.2 is an aliphatic chain having 10 to 18 carbons; and

R.sub.3 is pyrrolidino;

and functional homologues, isomers and pharmaceutically acceptable salts thereof.

2. The method of claim 1, where the growth of the cancer cells is inhibited by increasing ceramide levels in the cancer cells to a toxic level.

3. The method of claim 1, where R.sub.1 is a phenyl group.

4. The method of claim 1, where R.sub.1 is p-methoxyphenyl.

5. The method of claim 1, where R.sub.2 is C.sub.15 H.sub.31.

6. The method of claim 1, where the compound is 1-phenyl-2-palmitoylamino-3-pyrrolidino-1-propanol and pharmaceutically acceptable salts thereof.

7. A method for treating a patient having a drug resistant tumor sensitive to the compounds below, comprising the step of administering to the patient a therapeutically effective amount of a compound selected from the group consisting of compounds of the formula: ##STR6## where R.sub.1 is an aromatic structure, an alicyclic structure, a branched aliphatic structure or a linear aliphatic group having 5 to 15 carbons;

R.sub.2 is an aliphatic chain having 9 to 18 carbons; and

R.sub.3 is pyrrolidino;

and functional homologues, isomers and pharmaceutically acceptable salts thereof.

8. The method of claim 7, where R.sub.1 is a phenyl group.

9. The method of claim 7, where R.sub.1 is p-methoxyphenyl.

10. The method of claim 7, where R.sub.2 is C.sub.15 H.sub.31.

11. The method of claim 7, where the compound is 1-phenyl-2-palmitoylamino-3-pyrrolidino-1-propanol and pharmaceutically acceptable salts thereof.

12. A method for reducing tumor angiogenesis in a patient, wherein said angiogenesis is sensitive to the compounds below, comprising the step of administering to the patient a therapeutically effective amount of a compound selected from the group consisting of compounds of the formula: ##STR7## where R.sub.1 is an aromatic structure, an alicyclic structure, a branched aliphatic structure or a linear aliphatic group having 5 to 15 carbons;

R.sub.2 is an aliphatic chain having 9 to 18 carbons; and

R.sub.3 is pyrrolidino;

and functional homologues, isomers and pharmaceutically acceptable salts thereof.

13. The method of claim 12, where R.sub.1 is a phenyl group.

14. The method of claim 12, where R.sub.1 is p-methoxyphenyl.

15. The method of claim 12, where R.sub.2 is C.sub.15 H.sub.31.

16. The method of claim 12, where the compound is 1-phenyl-2-palmitoylamino-3-pyrrolidino-1-propanol and pharmaceutically acceptable salts thereof.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc